Literature DB >> 31339737

A Retrospective Assessment of Antecedent Pre-Exposure Prophylaxis Eligibility of HIV-Positive Women in the South.

Zandraetta Tims-Cook1.   

Abstract

African American women disproportionately endure the predominance of HIV infections among women, especially in the South. HIV pre-exposure prophylaxis (PrEP) is recognized as an effective prevention strategy for individuals at higher risk of HIV acquisition. Accordingly, PrEP is recommended in heterosexually active adult persons who are HIV negative; not in a monogamous relationship with an HIV-negative partner; and infrequently use condoms with a partner who is a bisexual male, HIV positive, or uses recreational intravenous (IV) drugs. Despite PrEP's acceptance among other groups at higher risk of HIV acquisition, studies indicate low use among African American women in the South. It is unclear whether underutilization results from a low perceived risk of HIV infection or from miscalculation of risk by clinicians. To ascertain the fitness of current PrEP indicators to evaluate HIV acquisition risk in heterosexual women, 102 HIV-positive women in Atlanta, GA, were queried about their awareness of and participation in higher risk heterosexual relationship dynamics before their HIV diagnosis. Risk awareness and behaviors were retrospectively assessed to determine whether the same women, now HIV positive, would have been considered for PrEP before their HIV diagnoses. When queried, 66% reported having only one sexual partner, 64% reported having sex ≥4 times with the partner from whom they acquired HIV, and >90% reported no knowledge of their partners' HIV-positive status or bisexual orientation. As demonstrated, heterosexual women with only one sexual partner and limited awareness of their partners' HIV-positive status or bisexual orientation remain at substantial risk of HIV acquisition without suitable risk approximation strategies.

Entities:  

Keywords:  HIV; PrEP; South; women

Mesh:

Year:  2019        PMID: 31339737     DOI: 10.1089/apc.2019.0046

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  6 in total

1.  Factors Associated with Intention to Initiate Pre-exposure Prophylaxis in Cisgender Women at High Behavioral Risk for HIV in Washington, D.C.

Authors:  Rachel K Scott; Shawnika J Hull; Jim C Huang; Megan Coleman; Peggy Ye; Pam Lotke; Jason Beverley; Patricia Moriarty; Dhikshitha Balaji; Allison Ward; Jennifer Holiday; Ashley R Brant; Martha Cameron; Rick Elion; Adam Visconti
Journal:  Arch Sex Behav       Date:  2022-05-27

Review 2.  US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review.

Authors:  Cherie Conley; Ragan Johnson; Keosha Bond; Sullivan Brem; Jasmine Salas; Schenita Randolph
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

3.  Contraception as a Potential Gateway to Pre-Exposure Prophylaxis: US Women's Pre-Exposure Prophylaxis Modality Preferences Align with Their Birth Control Practices.

Authors:  Sarah K Calabrese; Rachel W Galvao; John F Dovidio; Tiara C Willie; Cara B Safon; Clair Kaplan; Abigail Caldwell; Oni Blackstock; Nicole J Phillips; Trace S Kershaw
Journal:  AIDS Patient Care STDS       Date:  2020-03       Impact factor: 5.078

4.  Structural Barriers to HIV Prevention and Services: Perspectives of African American Women in Low-Income Communities.

Authors:  Shelby Rimmler; Carol Golin; James Coleman; Hayley Welgus; Sarah Shaughnessy; Leah Taraskiewicz; Alexandra F Lightfoot; Schenita D Randolph; Linda Riggins
Journal:  Health Educ Behav       Date:  2022-07-20

5.  The Associations of HIV Pre-Exposure Prophylaxis Interest and Sexual Risk Behaviors Among Young Black Women.

Authors:  Jaih B Craddock; Laurenia C Mangum; Gloria Aidoo-Frimpong; Darren L Whitfield
Journal:  AIDS Patient Care STDS       Date:  2021-07       Impact factor: 5.944

6.  Preexposure prophylaxis strategies for African-American women affected by mass incarceration.

Authors:  Joëlla W Adams; Maria R Khan; S E Bessey; Samuel R Friedman; James M McMahon; Mark N Lurie; Sandro Galea; Brandon D L Marshall
Journal:  AIDS       Date:  2021-03-01       Impact factor: 4.632

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.